Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Circulation

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/s1062-1458(03)00293-9PMID 12628950
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

  2002cited by this paper
• Ramipril and the development of diabetes.

  2001cited by this paper
• Clinical trials report

  2001cited by this paper
• Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data.

  2001cited by this paper
• Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus.

  2000cited by this paper
• Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

  2000cited by this paper
• Activation of glucose transport by AMP-activated protein kinase via stimulation of nitric oxide synthase.

  2000cited by this paper
• Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

  2000cited by this paper
• Report of the expert committee on the diagnosis and classification of diabetes mellitus.

  1999cited by this paper
• Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.

  1999cited by this paper
• ACE inhibition and glucose transport in insulinresistant muscle: roles of bradykinin and nitric oxide.

  1999cited by this paper
• Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

  1999cited by this paper
• Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats

  1998cited by this paper
• Evidence that nitric oxide increases glucose transport in skeletal muscle.

  1997cited by this paper
• Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

  1997cited by this paper
• The pathogenesis of type II diabetes mellitus. A polygenic disease.

  1996cited by this paper
• Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry.

  1996cited by this paper
• Differential effect of chronic treatment with two beta‐blocking agents on insulin sensitivity: the carvedilol‐metoprolol study

  1996cited by this paper
• Insulin Sensitivity in Obese Hypertensive Dyslipidemic Patients Treated with Enalapril or Atenolol

  1995cited by this paper
• Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor.

  1994cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.

  1994cited by this paper
• Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: Bradykinin may improve insulin resistance in dogs and humans

  1994cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

  1993cited by this paper
• Natural history and patterns of current practice in heart failure

  1993cited by this paper
• Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators.

  1993cited by this paper
• Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.

  1992cited by this paper
• Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

  1991cited by this paper
• Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure.

  1991cited by this paper
• Studies of left ventricular dysfunction (SOLVD)--rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction.

  1990cited by this paper
• Effect of antihypertensive treatment on blood-retinal barrier permeability to fluorescein in hypertensive Type 1 (insulin-dependent) diabetic patients with background retinopathy

  1989cited by this paper
• A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.

  1989cited by this paper
• Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  1987cited by this paper
• The effect of prostaglandins E1, E2 and F2 alpha and indomethacin on the sensitivity of glycolysis and glycogen synthesis to insulin in stripped soleus muscles of the rat.

  1985cited by this paper
• Glucose delivery: a modulator of glucose uptake in contracting skeletal muscle.

  1977cited by this paper
• A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin.

  1970cited by this paper

• Cardiovascular Pharmacotherapy and Glucose Metabolism: The Good, the Bad and the Unsightly.

  2025cites this paper
• Microbiome and metabolome explain the high-fat diet-induced diabetes development and diabetes resistance in Guizhou mini-pigs

  2025cites this paper
• Single cell RNA sequencing reveals the role of local renin-angiotensin system in regulating ovarian physiological cycle and promoting PCOS

  2025cites this paper
• Evidence of a bi-directional relationship between heart failure and diabetes: a strategy for the detection of glucose abnormalities and diabetes prevention in patients with heart failure

  2024cites this paper
• ACE inhibitors and their interaction with systems and molecules involved in metabolism

  2024cites this paper
• The effects of ecdysterone and enalapril on nitric oxide synthesis and the markers of oxidative stress in streptozotocin-induced diabetes in rats: a comparative study

  2024cites this paper
• Documento de consenso sobre el manejo de la diabetes tipo 2 y la insuficiencia cardíaca: Consejo Interamericano de Falla Cardíaca e Hipertensión Pulmonar (CIFACAH) de la Sociedad Interamericana de Cardiología (SIAC)

  2023cites this paper
• Cardio‐renal‐metabolic disease in primary care setting

  2023cites this paper
• Metabolic Approaches for the Treatment of Dilated Cardiomyopathy

  2023cites this paper
• Pharmacological approaches to the prevention of type 2 diabetes mellitus

  2023cites this paper
• Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials

  2022cites this paper
• Augmentation and Evaluation of an Olive Oil Based Polyherbal Combination against Diabetic Cardiomyopathy in Experimental Model of Rodents

  2022cites this paper
• Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting

  2022cites this paper
• Antihypertensive treatment improves glycemic control in patients with newly diagnosed type 2 diabetes mellitus: A prospective cohort study

  2022cites this paper
• Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence

  2022cites this paper
• Treating heart failure in patients with diabetes: the view of the cardiologist.

  2021cites this paper
• Obesity, metabolic syndrome, and inflammation: an update for anaesthetists caring for patients with obesity.

  2021cites this paper
• Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management

  2021cites this paper
• Diabetes and treatment of chronic heart failure in a large real‐world heart failure population

  2021cites this paper
• Diabetogenic effects of cardioprotective drugs

  2020cites this paper
• ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study

  2020cites this paper
• Myocardial Involvement in Chagas Disease and Insulin Resistance: A Non-Metabolic Model of Cardiomyopathy

  2020cites this paper
• Rhythm Control of Atrial Fibrillation in Heart Failure with Reduced Ejection Fraction

  2020cites this paper
• Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control

  2020cites this paper
• Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy

  2020cites this paper
• Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America.

  2019cites this paper
• Mediating the cardiovascular and renal effects of hyperhomocysteinemia in rats: Role of angiotensin П type I receptor

  2019cites this paper
• Effects of enalapril and paricalcitol treatment on diabetic nephropathy and renal expressions of TNF-α, p53, caspase-3 and Bcl-2 in STZ-induced diabetic rats

  2019cites this paper
• Metabolic effects of cardiovascular drugs.

  2019cites this paper
• Treatment of Patients with Heart failure and Type 2 Diabetes: a review of the literature

  2019cites this paper
• The relationship between glucose variability and insulin sensitivity and oxidative stress in subjects with prediabetes.

  2019cites this paper
• Medications affecting the biochemical conversion to type 2 diabetes: A systematic review and meta-analysis.

  2019cites this paper
• Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America.

  2019cites this paper
• Diabetic patients need higher furosemide doses: a report on acute and chronic heart failure patients.

  2019cites this paper
• Acute, local infusion of angiotensin II impairs microvascular and metabolic insulin sensitivity in skeletal muscle

  2018cites this paper
• Cardiovascular disease and ACE inhibitors: focusing on enalapril

  2018cites this paper
• Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology

  2018cites this paper
• EFFECT OF ENALAPRIL, LOSARTAN ALONE AND IN COMBINATION ON BLOOD GLUCOSE, SERUM INSULIN AND SERUM CORTISOL IN RABBITS.

  2018cites this paper
• Role of renin–angiotensin system in obesity associated disorders

  2018cites this paper
• Diabetic cardiomyopathy: a review of literature on clinical status and meta-analysis of tissue doppler diagnostic method and the clinical value of intensive glycemic control

  2018cites this paper
• Sacubitril/valsartan in PARADIGM-HF - Authors' reply.

  2017cites this paper
• Induction of Type 2 Diabetes Mellitus with Antihypertensive Therapy: Is There Any Role of Alpha Adducin, ACE, and IRS-1 Gene?

  2017cites this paper
• Korean Guidelines for Diagnosis and Management of Chronic Heart Failure

  2017cites this paper
• A COMPREHENSIVE STUDY ON LITERATURE EVIDENCE, CLINICAL STUDIES AND PRACTICES OF HERBAL DRUGS FOR DIABETIC NEUROPATHY AND CARDIOMYOPATHY

  2017cites this paper
• Dietary Fat Intake Modulates Effects of a Frequent ACE Gene Variant on Glucose Tolerance with association to Type 2 Diabetes

  2017cites this paper
• Comparing six antihypertensive medication classes for preventing new‐onset diabetes mellitus among hypertensive patients: a network meta‐analysis

  2017cites this paper
• A comprehensive review of the bioenergetics of fatty acid and glucose metabolism in the healthy and failing heart in nondiabetic condition

  2017cites this paper
• ACEIs/ARBs for the prevention of type 2 diabetes in patients with cardiovascular diseases: a systematic review and meta-analysis

  2016cites this paper
• [Bidirectional impact of two chronic diseases: heart failure and diabetes mellitus].

  2016cites this paper
• Computational Drug Repositioning Using Continuous Self-Controlled Case Series

  2016cites this paper
• The adipose tissue and the involvement of the renin–angiotensin–aldosterone system in cardiometabolic syndrome

  2016cites this paper
• Selected Issues of Etiology and Pathogenesis , Prognosis and Treatment

  2016cites this paper
• Therapeutic Challenges in Diabetes Prevention: We Have Not Found the “Exercise Pill”

  2015cites this paper
• Electrocardiographic and Echocardiographic Imaging of the Heart of Athletes and Patients with Hypertension

  2015cites this paper
• Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease.

  2015cites this paper
• Deranged Cardiac Metabolism and the Pathogenesis of Heart Failure.

  2015cites this paper
• A COMPARATIVE STUDY OF THE EFFECTS OF THE ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND CALCIUM CHANNEL BLOCKERS ON THE CARDIOVASCULAR OUTCOME IN HYPERTENSIVE PATIENTS WITH TYPE-2 DIABETES MELLITUS

  2015cites this paper
• Diabetes mellitus and heart failure - an overview of epidemiology and management

  2015cites this paper
• The Bi-directional Impact of Two Chronic Illnesses: Heart Failure and Diabetes - A review of the Epidemiology and Outcomes.

  2015cites this paper
• ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary

  2014cites this paper
• Diabetic cardiomyopathy: from pathophysiology to treatment.

  2014cites this paper
• Association between type-2 diabetes mellitus and post-discharge outcomes in heart failure patients: findings from the RICA registry.

  2014cites this paper
• Impact of Left Ventricular Assist Device on Diabetes Management: An Evaluation through Case Analysis and Clinical Impact

  2014cites this paper
• Antihypertensive drugs and glucose metabolism.

  2014cites this paper
• Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications.

  2014cites this paper
• New-Onset Diabetes in Heart Failure Patients: A Complex Relationship with Clinical Implications

  2014cites this paper
• Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways.

  2014cites this paper
• [ESC guidelines on diabetes, pre-diabetes and diseases of the cardiovascular system developed in cooperation with the EASD].

  2013cites this paper
• Obesity and cardiovascular disease: role of adipose tissue, inflammation, and the renin-angiotensin-aldosterone system

  2013cites this paper
• The renin-angiotensin system in adipose tissue and its metabolic consequences during obesity.

  2013cites this paper
• Transgenic Mice Overexpressing Renin Exhibit Glucose Intolerance and Diet-Genotype Interactions

  2013cites this paper
• ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

  2013cites this paper
• Antihypertensive treatment in diabetic patients. Review of current data.

  2013cites this paper
• Improvement in Glycemic Control After Left Ventricular Assist Device Implantation in Advanced Heart Failure Patients With Diabetes Mellitus

  2013cites this paper
• Cardiogenic diabetes

  2013cites this paper
• Diabetes und kardiovaskuläre Erkrankungen, Zusammenfassung der ESC-Leitlinien 2013

  2013cites this paper
• Activation of systemic, but not local, renin–angiotensin system is associated with upregulation of TNF-α during prolonged fasting in northern elephant seal pups

  2013cites this paper
• How should we treat hypertension and dyslipidemia in patients with prediabetes?

  2013cites this paper
• Metabolic syndrome in children with chronic kidney disease and after renal transplantation

  2013cites this paper
• Angiotensin converting enzyme inhibitors for prevention of new-onset type 2 diabetes mellitus: a meta-analysis of 72,128 patients.

  2013cites this paper
• Effects of antihypertensive treatments on incidence of diabetes: A case-control study

  2012cites this paper
• Congestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvement.

  2012cites this paper
• [Heart failure and development of type 2 diabetes mellitus].

  2012cites this paper
• ACE Inhibitors and Angiotensin Receptor Antagonists and the Incidence of New-Onset Diabetes Mellitus

  2012cites this paper
• The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome.

  2012cites this paper
• Prevention of Type 2 Diabetes Mellitus Through Inhibition of the Renin-Angiotensin System

  2012cites this paper
• Microvascular dysfunction and the development of muscle insulin resistance

  2012cites this paper
• Preventive pharmacotherapy in type 2 diabetes mellitus

  2012cites this paper
• The renin‐angiotensin system: a link between obesity, inflammation and insulin resistance

  2012cites this paper
• Myocardial Insulin Resistance: An Overview of Its Causes, Effects, and Potential Therapy

  2012cites this paper
• Progression rate of newly diagnosed impaired fasting glycemia to type 2 diabetes mellitus: A study using the National Healthcare Group Diabetes Registry in Singapore

  2012cites this paper
• The adipose tissue renin-angiotensin system and metabolic disorders: a review of molecular mechanisms

  2012cites this paper
• Congestive Heart Failure and Diabetes: Balancing Glycemic Control with Heart Failure Improvement

  2012cites this paper
• Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation.

  2012cites this paper
• The role of renin angiotensin system intervention in stage B heart failure.

  2012cites this paper
• Metabolic remodelling in human heart failure.

  2011cites this paper
• The Role of Angiotensin II in Skeletal Muscle Metabolism

  2011cites this paper
• Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials.

  2011cites this paper
• Mechanistic and clinical aspects of renin-angiotensin-aldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease.

  2011cites this paper
• Vascular smooth muscle insulin resistance, but not hypertrophic signaling, is independent of angiotensin II-induced IRS-1 phosphorylation by JNK.

  2011cites this paper